Baxalta’s BAX 855, a pegylated full-length recombinant factor VIII (rFVIII) based on the licensed rFVIII product Advate, was designed to increase half-life and potentially reduce the frequency of prophylactic infusions while maintaining hemostatic efficacy.
Investigators at Vanderbilt University Medical Center retrospectively extracted data from medical records of IBD patients treated with intravenous immune globulin (IVIG) used to treat these difficult cases.
The efficacy of Baxter International’s investigational recombinant von Willebrand factor (rVWF) was rated “excellent” (96.9%) or “good” (3.1%) for treatment of 192 bleeding events in 22 patients with severe von Willebrand disease who were enrolled in a Phase 3 clinical trial.
Will the evolving therapeutic guidelines for treating diabetes, as well as managing its risks and complications, stem the tide of this costly and sometimes deadly disease?
In results from a Phase 3b trial in 168 patients needing urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA) therapy, 78 patients (90 percent) treated with CSL Behring’s four-factor prothrombin complex concentrate (Kcentra; 4F-PCC) achieved effective hemostasis, compared with 61 patients (75 percent) treated with plasma.
A single-center proof-of-concept study was conducted to learn whether intravenous immunoglobulin (IVIG) can control acute cutaneous lupus erythematosus (CLE) and thus replace current systemic immunosuppressive therapy that causes severe side effects and adverse reactions.
In the debate between personal freedom and government mandates, healthcare professionals are a reliable resource for vaccine information.
With an estimated 79 million Americans currently infected with HPV and an additional 14 million infections occurring each year, why are U.S. vaccination rates stagnantly low?
The staggering increase in autism prevalence around the world has sparked fears among parents and distorted the facts about this unexplained disorder.
The measles resurgence is introducing a whole new generation of physicians to a once-eradicated
and potentially deadly disease.
Chronic and acute kidney failure can be the result of many causes, and its prevalence is growing at historic rates, but it is no longer a death sentence.
Recent events have re-energized the ongoing debate about mandatory vaccines for children in the U.S. It remains to be seen which side of the controversy will prevail.